Price Alert

PureTech Health (PRTC)

NASDAQ: PRTC · Real-Time Price · USD

16.23

0.41 (2.59%)

At close: Sep 04, 2025, 3:57 PM

16.50

1.66%

After-hours: Sep 04, 2025, 04:00 PM EDT

2.59% (1D)

Bid	15.71
Market Cap	392.25M
Revenue (ttm)	4.32M
Net Income (ttm)	53.51M
EPS (ttm)	1.7
PE Ratio (ttm)	9.55
Forward PE	-3.66
Analyst	Buy

Ask	18.53
Volume	1,723
Avg. Volume (20D)	4,130
Open	16.05
Previous Close	15.82
Day's Range	15.86 - 16.57
52-Week Range	13.30 - 24.99
Beta	0.86

About PRTC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRTC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PRTC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

PureTech Health has released their quartely earnings on Aug 28, 2025:

Revenue of $1.85M misses estimates by $739K, with 542.71% YoY growth.

EPS of -0.19 exceeds estimates by 3.61, with -26.67% YoY decline.

Next Earnings Release

PureTech Health is scheduled to release its earnings on Apr 29, 2026, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

8 months ago

+8.85%

PureTech Health shares are trading higher after th... Unlock content with Pro Subscription

News

1 week ago · businesswire.com

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.

2 weeks ago · businesswire.com

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.

2 weeks ago · businesswire.com

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

3 weeks ago · businesswire.com

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.

3 weeks ago · businesswire.com

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.

1 month ago · businesswire.com

PureTech Announces Leadership Transition

BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.

1 month ago · businesswire.com

PureTech Announces Board Change

BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.

2 months ago · businesswire.com

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.